Literature DB >> 20043097

Proteolipid protein 2 is associated with melanoma metastasis.

Yoshiko Sonoda1, Masako Warita, Takaharu Suzuki, Hiroki Ozawa, Yusuke Fukuda, Megumi Funakoshi-Tago, Tadashi Kasahara.   

Abstract

The metastasis of malignant tumor cells from the primary tumor to distant sites in the body is a complex process. To identify genes that may be essential for metastasis, we established poorly metastatic mouse melanoma cells, namely Y925F-mutated FAK-transfected cells (Y925F cells), from the highly metastatic mouse melanoma cell line B16F10, and performed expression analyses. The expression of phospholipid protein 2 (PLP2) was markedly down-regulated in the Y925F cells. To elucidate the function of PLP2, we established melanoma cells overexpressing PLP2. We found that PLP2 enhanced proliferation, adhesion, invasion, and MMP-2 secretion in vitro, and tumor metastasis in vivo. These results suggest that PLP2 aids metastasis. Furthermore, we showed that PLP2 binds specifically to PI3K, thus activating Akt.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20043097

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

1.  Knockdown of proteolipid protein 2 or focal adhesion kinase with an artificial microRNA reduces growth and metastasis of B16BL6 melanoma cells.

Authors:  Hiroki Ozawa; Yoshiko Sonoda; Takaharu Suzuki; Naomi Yoshida-Hoshina; Megumi Funakoshi-Tago; Tadashi Kasahara
Journal:  Oncol Lett       Date:  2011-09-16       Impact factor: 2.967

2.  Identification of PLP2 and RAB5C as novel TPD52 binding partners through yeast two-hybrid screening.

Authors:  Hamideh Shahheydari; Sarah Frost; Brian J Smith; Guy E Groblewski; Yuyan Chen; Jennifer A Byrne
Journal:  Mol Biol Rep       Date:  2014-03-07       Impact factor: 2.316

3.  Cancer cell proliferation is inhibited by specific modulation frequencies.

Authors:  J W Zimmerman; M J Pennison; I Brezovich; N Yi; C T Yang; R Ramaker; D Absher; R M Myers; N Kuster; F P Costa; A Barbault; B Pasche
Journal:  Br J Cancer       Date:  2011-12-01       Impact factor: 7.640

4.  PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma.

Authors:  Hua Bai; Yudi Zhu; Peipei Xu; Bing Chen
Journal:  Biomed Res Int       Date:  2020-06-10       Impact factor: 3.411

5.  Reduced expression of proteolipid protein 2 increases ER stress-induced apoptosis and autophagy in glioblastoma.

Authors:  Zichao Feng; Wenjing Zhou; Jiwei Wang; Qichao Qi; Mingzhi Han; Yang Kong; Yaotian Hu; Yulin Zhang; Anbin Chen; Bin Huang; Anjing Chen; Di Zhang; Wenjie Li; Qing Zhang; Rolf Bjerkvig; Jian Wang; Frits Thorsen; Xingang Li
Journal:  J Cell Mol Med       Date:  2019-11-28       Impact factor: 5.310

6.  Identification of a Five-Gene Signature and Establishment of a Prognostic Nomogram to Predict Progression-Free Interval of Papillary Thyroid Carcinoma.

Authors:  Mengwei Wu; Hongwei Yuan; Xiaobin Li; Quan Liao; Ziwen Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-15       Impact factor: 5.555

7.  Haploid genetic screens identify an essential role for PLP2 in the downregulation of novel plasma membrane targets by viral E3 ubiquitin ligases.

Authors:  Richard T Timms; Lidia M Duncan; Iva A Tchasovnikarova; Robin Antrobus; Duncan L Smith; Gordon Dougan; Michael P Weekes; Paul J Lehner
Journal:  PLoS Pathog       Date:  2013-11-21       Impact factor: 6.823

8.  Proteolipid Protein 2 Overexpression Indicates Aggressive Tumor Behavior and Adverse Prognosis in Human Gliomas.

Authors:  Yi-Hsuan Chen; Dueng-Yuan Hueng; Wen-Chiuan Tsai
Journal:  Int J Mol Sci       Date:  2018-10-26       Impact factor: 5.923

9.  E-Cadherin, NFATC3, and PLP2 Are Differentially Methylated in Multiple Cancers.

Authors:  Mary J Lotesto; Christopher J Wallace; Stacey L Raimondi
Journal:  Epigenet Insights       Date:  2020-10-20

10.  Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2.

Authors:  Zhenhua Ding; Sun Jian; Xuebiao Peng; Yimin Liu; Jianyu Wang; Li Zheng; Chengshan Ou; Yinghui Wang; Weixia Zeng; Meijuan Zhou
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.